The Department of Health and Human Services (HHS) Office of Inspector General (OIG) has concluded that an arrangement through which a pharmaceutical manufacturer covered some patient expenses connected with a lengthy autologous T-cell treatment followed by an extended period of patient monitoring posed a sufficiently low risk of fraud and abuse that the office would not impose... Read More